Nicholas Keen

Nicholas Keen

UNVERIFIED PROFILE

Are you Nicholas Keen?   Register this Author

Register author
Nicholas Keen

Nicholas Keen

Publications by authors named "Nicholas Keen"

Are you Nicholas Keen?   Register this Author

27Publications

1799Reads

13Profile Views

Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening.

Cell 2017 Jul;170(3):577-592.e10

Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2017.07.005DOI Listing
July 2017

Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 Inhibitors.

J Med Chem 2016 12 1;59(24):11079-11097. Epub 2016 Dec 1.

Department of Biochemistry, Vanderbilt-Ingram Cancer Center, Vanderbilt University , Nashville, Tennessee 37232 United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.6b01303DOI Listing
December 2016

Discovery and mechanistic study of a small molecule inhibitor for motor protein KIFC1.

ACS Chem Biol 2013 Oct 16;8(10):2201-8. Epub 2013 Aug 16.

Discovery Sciences and ‡Oncology Innovative Medicine Unit, AstraZeneca R&D Boston, Waltham, Massachusetts 02451, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/cb400186wDOI Listing
October 2013

Mitotic drivers--inhibitors of the Aurora B Kinase.

Cancer Metastasis Rev 2009 Jun;28(1-2):185-95

AstraZeneca Pharmaceuticals, R&D Boston, Waltham, MA 02451, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-009-9184-9DOI Listing
June 2009

Validating Aurora B as an anti-cancer drug target.

J Cell Sci 2006 Sep 15;119(Pt 17):3664-75. Epub 2006 Aug 15.

Faculty of Life Sciences, Michael Smith Building, Oxford Road, University of Manchester, Manchester, M13 9PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1242/jcs.03145DOI Listing
September 2006

Progress in the development of selective inhibitors of aurora kinases.

Curr Top Med Chem 2005 ;5(8):807-21

Cancer and Infection Research Area, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568026054637719DOI Listing
October 2005

Progress in the development of selective inhibitors of Aurora kinases.

Curr Top Med Chem 2005 ;5(2):199-213

Cancer and Infection Research Area, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire, UK, SK10 4TG.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568026053507651DOI Listing
June 2005

The Ipl1/Aurora kinase family: methods of inhibition and functional analysis in mammalian cells.

Methods Mol Biol 2005 ;296:371-81

School of Biological Sciences, University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1385/1-59259-857-9:371DOI Listing
March 2005

Aurora-kinase inhibitors as anticancer agents.

Nat Rev Cancer 2004 Dec;4(12):927-36

Cancer and Infection Research Area, AstraZeneca Pharmaceuticals, Mereside, Alderley Park, Cheshire, SK10 4TG, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc1502DOI Listing
December 2004